

GLOBAL BIOCHIP MARKETS: MICROARRAYS AND LAB-ON-A-CHIP



BIO049F
April 2016

Jon Evans
Project Analyst

ISBN: 1-62296-277-X



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE	2
SCOPE AND FORMAT OF REPORT	3
<i>TABLE A SCOPE OF REPORT</i>	3
METHODOLOGY	4
INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	5
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR BIOCHIP PRODUCTS BY END USE, THROUGH 2020 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET TRENDS FOR BIOCHIP PRODUCTS BY END USE, 2014-2020 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
INTRODUCTION	10
<i>TABLE 1 BIOLOGY DOWNSIZING REVOLUTION</i>	11
BIOCHIP TYPES	11
<i>TABLE 2 COMPARISON OF TWO MAJOR BIOCHIP TYPES</i>	12
<i>TABLE 3 BIOCHIP NOMENCLATURE</i>	13
MARKET POTENTIAL OF BIOCHIPS	14
<i>TABLE 4 GLOBAL MARKET FOR BIOCHIP PRODUCTS BY BIOCHIP TYPE, THROUGH 2020 (\$ MILLIONS)</i>	14
DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS	15
<i>TABLE 5 DRIVING FORCES FOR BIOCHIPS KEY MARKET GROWTH</i>	16
THE BIOCHIP INDUSTRY	16
<i>TABLE 6 COMPARISON OF BIOCHIPS INDUSTRIES</i>	16
CHAPTER 4 MICROARRAY TECHNOLOGIES	19
INTRODUCTION	19
<i>TABLE 7 THE NANOSCALE WORLD</i>	19
<i>TABLE 8 TYPES OF MICROARRAY</i>	19
<i>TABLE 9 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES</i>	20
DNA MICROARRAY TECHNOLOGIES	22
DNA MICROARRAY TYPES	22
<i>FIGURE 1 MICROARRAY FEATURE DENSITY</i>	22
<i>FIGURE 2 MICROARRAY RESOLUTION</i>	22
<i>TABLE 10 MICROARRAY GENOME CONTENT</i>	23
<i>TABLE 11 DNA MICROARRAY PLATFORM FEATURES</i>	23
DNA MICROARRAY APPLICATIONS	24
<i>TABLE 12 APPLICATIONS OF DNA MICROARRAY</i>	25

TOPIC	PAGE NO.
<i>TABLE 13 COMPARISON OF GENETIC ANALYSIS TECHNOLOGIES</i>	26
<i>FIGURE 3 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES AT MAF5 AND MAF1</i>	27
SNP ANALYSIS	28
<i>TABLE 14 SNP MEASUREMENT PLATFORMS</i>	28
EPIGENETIC ANALYSIS	29
<i>FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS`</i>	30
CYTOGENETIC ANALYSIS	31
<i>TABLE 15 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES</i>	32
MICRO-RNA ANALYSIS	33
<i>TABLE 16 WORKFLOW FOR A MICRO-RNA EXPERIMENT</i>	34
BEAD-BASED ARRAYS	34
<i>TABLE 17 COMPARISON OF BEAD-BASED ARRAYS AND PLANAR MICROARRAYS</i>	34
CATALOG AND CUSTOM DNA MICROARRAYS	35
PROTEIN MICROARRAY TECHNOLOGIES	35
INTRODUCTION	35
<i>FIGURE 5 IMPORTANCE OF PROTEINS</i>	35
PROTEOMICS WORKFLOW	36
<i>FIGURE 6 PROTEIN ANALYSIS APPROACHES CONTRASTED</i>	36
PROTEIN MICROARRAY DESIGN FEATURES	37
<i>TABLE 18 PROTEIN MICROARRAY PLATFORMS</i>	37
PROTEIN MICROARRAY APPLICATIONS AS RESEARCH TOOLS	38
<i>TABLE 19 PROTEIN MICROARRAYS AS RESEARCH TOOLS</i>	38
PROTEIN MICROARRAY TYPES	40
<i>TABLE 20 PRODUCT TYPES OF PROTEIN MICROARRAY</i>	40
PROTEIN MICROARRAY TECHNOLOGY CHALLENGES	42
<i>TABLE 21 TECHNICAL CHALLENGES OF PROTEIN MICROARRAY</i>	42
EMERGING MICROARRAY TECHNOLOGIES	44
<i>TABLE 22 EMERGING MICROARRAY TECHNOLOGIES</i>	44
GLYCOMICS MICROARRAYS	44
TISSUE MICROARRAYS	45
CHAPTER 5 LAB-ON-A-CHIP TECHNOLOGIES	48
INTRODUCTION	48
<i>TABLE 23 LOAC PRODUCT LIFE CYCLE STAGE</i>	48
SUBSTRATE MATERIALS	49
<i>TABLE 24 BIOCHIPS SUBSTRATE MATERIALS</i>	49
LOAC TYPES	50
<i>TABLE 25 TYPES OF LOAC</i>	50
IN VITRO PROTEOMICS	50
ELECTROPHORESIS ON A CHIP	51
STRUCTURAL PROTEOMICS	51
PCR ON A CHIP	52
IMMUNOASSAY ON A CHIP	53
MASS SPECTROMETRY ON CHIP	54
NEXT-GENERATION SEQUENCING ON CHIP	54
<i>TABLE 26 WORKFLOW COMPARISON OF SELECTED NEXT-GENERATION DNA SEQUENCING PLATFORMS</i>	55
<i>TABLE 27 BIOCHIP CONTENT IN NEXT-GENERATION SEQUENCING MACHINES</i>	55

TOPIC	PAGE NO.
LOAC APPLICATIONS	56
TABLE 28 SEGMENTS OF LOAC MARKET	57
TABLE 29 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS	58
ORGAN ON CHIP	58
LOAC TECHNOLOGY CHALLENGES	59
TABLE 30 TECHNICAL CHALLENGES OF LOAC TECHNOLOGY	59
CHAPTER 6 DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS	62
INTRODUCTION	62
TABLE 31 BIOCHIP KEY LIFE SCIENCES MARKET SEGMENTS	62
DRUG INDUSTRY CHALLENGES	63
DRUG DISCOVERY AND DEVELOPMENT PROCESS	64
FIGURE 7 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE	64
TABLE 32 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT	65
DRUG TARGET IDENTIFICATION	66
DRUG DISCOVERY	66
Structural Biology	67
Lead Generation	67
Lead Optimization	69
Process R&D	70
Preclinical and Clinical Trials	70
NEEDS IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS	70
TABLE 33 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT	71
FIGURE 8 VALIDATION GAP FOR FUTURE DRUG TARGETS	73
CHAPTER 7 DIAGNOSTICS APPLICATIONS	75
INTRODUCTION	75
TABLE 34 DIAGNOSTICS PARADIGM SHIFT	75
HOW DIAGNOSTICS DIFFER FROM RESEARCH TOOLS	76
TABLE 35 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC ASSAY	76
HOW BIOLOGICAL CONTENT DRIVES THE GROWTH OF DIAGNOSTICS	77
TABLE 36 BIOMARKERS USED IN BIOCHIP-BASED DIAGNOSTICS	77
FACTORS IN CLINICAL ACCEPTANCE OF BIOMARKER-BASED TESTS	79
TABLE 37 RATE OF ADOPTION OF DNA MICROARRAY DIAGNOSTICS TESTS	79
MOLECULAR DIAGNOSTICS	80
INTRODUCTION	80
MARKET CHALLENGES FOR DNA-BASED MDX PLATFORMS	81
TABLE 38 COMPARISON OF DNA-BASED MDX PLATFORMS	81
TABLE 39 FACTORS AFFECTING PENETRATION OF NEXT-GENERATION FORMATS INTO THE MDX MARKET	82
DIAGNOSTICS MARKET SEGMENTS	84
TEST SENSITIVITY AND SPECIFICITY	85
FIGURE 9 SENSITIVITY AND SPECIFICITY	85
REGULATORY STATUS	86
BIOCHIPS CANCER APPLICATIONS	87
CANCER OVERVIEW	87
TABLE 40 U.S. INCIDENCE FOR SELECTED CANCERS, 2012	87
BLADDER CANCER	88

TOPIC	PAGE NO.
<i>TABLE 41 STATUS OF ADVANCED BLADDER CANCER DIAGNOSTICS</i>	89
BREAST CANCER	90
Breast Cancer Screening	90
Prognosis and Pharmacogenetics Tests	91
<i>TABLE 42 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION</i>	92
Breast Cancer MDx Platforms	92
<i>TABLE 43 BREAST CANCER MDX TECHNOLOGY PLATFORMS</i>	92
<i>TABLE 44 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS</i>	94
CERVICAL CANCER	98
<i>TABLE 45 STATUS OF ADVANCED HPV DIAGNOSTICS</i>	99
COLORECTAL CANCER	102
Conventional Colorectal Cancer Screening Tests	102
<i>TABLE 46 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER</i>	102
Molecular Colorectal Cancer Diagnostics Tests	103
<i>TABLE 47 STATUS OF ADVANCED COLORECTAL CANCER DIAGNOSTICS</i>	104
CANCER OF UNKNOWN PRIMARY (CUP)	105
<i>TABLE 48 MDX TECHNOLOGY PLATFORMS FOR DETECTING CUP</i>	107
KIDNEY CANCER	108
<i>TABLE 49 STATUS OF ADVANCED KIDNEY CANCER DIAGNOSTICS</i>	108
LEUKEMIA	109
<i>TABLE 50 STATUS OF ADVANCED LEUKEMIA DIAGNOSTICS</i>	110
LIVER CANCER	112
<i>TABLE 51 STATUS OF LIVER CANCER NEXT-GENERATION DX TESTS</i>	112
LYMPHOMA	113
<i>TABLE 52 STATUS OF ADVANCED LYMPHOMA CANCER DIAGNOSTICS</i>	114
LUNG CANCER	114
<i>TABLE 53 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER (%)</i>	114
<i>TABLE 54 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS</i>	116
MELANOMA	119
<i>TABLE 55 STATUS OF ADVANCED MELANOMA DIAGNOSTICS</i>	120
OVARIAN CANCER	121
<i>TABLE 56 EARLY SCREENING TESTS FOR OVARIAN CANCER</i>	122
<i>TABLE 57 STATUS OF OVARIAN CANCER NEXT-GENERATION DIAGNOSTICS TESTS</i>	123
PANCREATIC CANCER	124
<i>TABLE 58 STATUS OF ADVANCED PANCREATIC CANCER DIAGNOSTICS</i>	125
PROSTATE CANCER	126
<i>TABLE 59 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS</i>	127
THYROID CANCER	130
<i>TABLE 60 STATUS OF ADVANCED THYROID CANCER DIAGNOSTICS</i>	131
SUMMARY OF ADVANCED CANCER DIAGNOSTICS	131
<i>TABLE 61 NEXT-GENERATION DX TEST SUMMARY BY INDICATION AND TECHNOLOGY</i>	132
WARFARIN SENSITIVITY	133
<i>TABLE 62 IMPORTANCE OF CYP GENES IN DRUG METABOLISM (%)</i>	134
<i>TABLE 63 STATUS OF ADVANCED WARFARIN CYP PHARMACOGENETIC DIAGNOSTICS</i>	135

TOPIC	PAGE NO.
INFECTIOUS DISEASES	137
TUBERCULOSIS	137
HOSPITAL-ACQUIRED INFECTIONS	137
<i>TABLE 64 STATUS OF MRSA AND C. DIFFICILE ADVANCED DIAGNOSTICS</i>	138
INFLUENZA	139
<i>TABLE 65 STATUS OF INFLUENZA ADVANCED DIAGNOSTICS</i>	139
SEXUALLY TRANSMITTED DISEASES	141
<i>TABLE 66 STATUS OF CT/NG ADVANCED DIAGNOSTICS</i>	141
OTHER INFECTIOUS DISEASES	142
NEUROLOGICAL	143
ALZHEIMER'S DISEASE	143
<i>TABLE 67 DIAGNOSTICS APPROACHES FOR ALZHEIMER'S DISEASE</i>	143
<i>TABLE 68 STATUS OF ALZHEIMER'S DISEASE ADVANCED DIAGNOSTICS TESTS</i>	144
SCHIZOPHRENIA	145
CARDIAC DISORDERS	146
CONGESTIVE HEART FAILURE	146
<i>TABLE 69 BNP MOLECULAR DIAGNOSTICS TESTS FOR CONGESTIVE HEART FAILURE</i>	146
CYSTIC FIBROSIS	148
<i>TABLE 70 ADVANCED DIAGNOSTICS TESTS FOR CYSTIC FIBROSIS</i>	148
NONINVASIVE PRENATAL SCREENING	150
<i>TABLE 71 NEXT-GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS INDUSTRY</i>	150
IMMUNE DISORDERS	151
HLA TYPING	151
<i>TABLE 72 HLA TESTING MARKET</i>	152
AUTOIMMUNE TESTING	154
CHAPTER 8 BIOCHIPS INDUSTRY	156
BIOCHIPS INDUSTRY ACQUISITIONS, 2012 TO 2015	156
<i>TABLE 73 ACQUISITIONS IN THE BIOCHIPS INDUSTRY, 2012-2015</i>	156
BIOCHIPS INDUSTRY STRATEGIC ALLIANCES	159
MICROARRAY INDUSTRY STRATEGIC ALLIANCES	159
<i>TABLE 74 MICROARRAY INDUSTRY STRATEGIC ALLIANCES, 2012-2013</i>	160
LOAC INDUSTRY STRATEGIC ALLIANCES	164
<i>TABLE 75 LOAC/NGS INDUSTRY STRATEGIC ALLIANCES, 2012-2013</i>	164
LOAC INDUSTRY	173
LOAC INDUSTRY OVERVIEW	173
<i>TABLE 76 LOAC COMPETITOR LANDSCAPE</i>	173
LOAC INSTRUMENT INDUSTRY	175
<i>TABLE 77 LEADING LOAC INSTRUMENT MANUFACTURERS</i>	175
LOAC DNA ANALYZER INDUSTRY	176
<i>TABLE 78 FORENSIC APPLICATIONS FOR LOAC-BASED DNA ANALYZERS</i>	176
LOAC DIAGNOSTICS INDUSTRY	177
<i>TABLE 79 LOAC DIAGNOSTICS INDUSTRY</i>	177
ION CHANNEL SCREENING INDUSTRY	178
<i>TABLE 80 ION CHANNEL SCREENING INDUSTRY</i>	178
DIGITAL PCR INDUSTRY	179
<i>TABLE 81 DIGITAL PCR INDUSTRY</i>	179

TOPIC	PAGE NO.
INFLUENTIAL UNIVERSITIES IN THE LOAC INDUSTRY	180
<i>TABLE 82 LOAC UNIVERSITY SPIN-OFFS</i>	180
ROLE OF LOAC ACQUISITIONS IN LIFE SCIENCES INDUSTRY	181
<i>TABLE 83 KEY LOAC ACQUISITIONS BY LEADING LIFE SCIENCE COMPANIES</i>	181
NEXT-GENERATION SEQUENCING INSTRUMENT INDUSTRY	182
<i>TABLE 84 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL PHASE</i>	182
MICROARRAY INDUSTRY	183
SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY	183
<i>TABLE 85 SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY</i>	184
LABEL-FREE DETECTION INDUSTRY	184
<i>TABLE 86 LABEL-FREE DETECTION INDUSTRY</i>	184
NANOARRAY INDUSTRY	186
<i>TABLE 87 NANOARRAY INDUSTRY</i>	186
PEPTIDE MICROARRAY INDUSTRY	186
<i>TABLE 88 KEY PEPTIDE MICROARRAY COMPANIES</i>	187
ANTIBODY MICROARRAY INDUSTRY	188
<i>TABLE 89 KEY ANTIBODY MICROARRAY COMPANIES</i>	188
ANTIBODY REAGENTS INDUSTRY	188
<i>TABLE 90 ESTIMATED MARKET SHARE FOR KEY ANTIBODY REAGENTS COMPANIES, 2012</i>	189
BIOCHIPS DIAGNOSTICS INDUSTRY	189
MULTIPLEX PROTEIN DIAGNOSTICS INDUSTRY	190
<i>TABLE 91 MULTIPLEX PROTEIN IN VITRO DIAGNOSTICS COMPANIES</i>	190
CIRCULATING TUMOR CELL INDUSTRY	192
<i>TABLE 92 CTC BIOCHIPS INDUSTRY</i>	192
PRENATAL DIAGNOSTICS INDUSTRY	194
<i>TABLE 93 NORTH AMERICAN TEST COSTS AND PRICES, 2014 (\$)</i>	194
<i>TABLE 94 NEXT-GENERATION SEQUENCING-BASED, NONINVASIVE PRENATAL DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2014 (%)</i>	195
<i>TABLE 95 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS</i>	196
POC CD4 COUNTING INDUSTRY	197
<i>TABLE 96 POC CD4 INDUSTRY</i>	197
AGRICULTURAL INDUSTRY	198
<i>TABLE 97 BIOCHIPS-BASED COMPANIES IN AGRICULTURAL INDUSTRY</i>	198
CHINA'S BIOCHIP INDUSTRY	200
<i>TABLE 98 CHINA BIOCHIP INDUSTRY</i>	201
CHAPTER 9 BIOCHIPS MARKETS	204
DRIVING FORCES FOR BIOCHIPS GROWTH	204
<i>TABLE 99 KEY MARKET GROWTH DRIVING FORCES FOR BIOCHIPS</i>	204
GLOBAL BIOCHIPS MARKET	205
<i>TABLE 100 GLOBAL MARKET FOR BIOCHIP PRODUCTS BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	205
<i>TABLE 101 GLOBAL MARKET FOR BIOCHIPS BY END-USE INDUSTRY, THROUGH 2020 (\$ MILLIONS)</i>	206
<i>TABLE 102 PROPERTIES OF BIOCHIPS SUBSTRATE MATERIALS</i>	207

TOPIC	PAGE NO.
<i>TABLE 103 GLOBAL MARKET FOR BIOCHIPS BY SUBSTRATE MATERIAL, THROUGH 2020 (\$ MILLIONS)</i>	207
DNA MICROARRAY MARKETS	208
DNA MICROARRAY MARKET BY END-USE INDUSTRY	208
<i>TABLE 104 GLOBAL MARKET FOR DNA MICROARRAYS BY END USE, THROUGH 2020 (\$ MILLIONS)</i>	208
DNA MICROARRAY MARKET BY ANALYSIS TYPE	210
<i>TABLE 105 GLOBAL CONTRIBUTION OF DNA MICROARRAYS BY ANALYSIS TYPE, 2015 (%)</i>	210
<i>FIGURE 10 ENTRIES TO MIRNA DATABASE, 2002-2014 (NO.)</i>	212
DNA MICROARRAY MARKET BY SUBSTRATE MATERIAL	212
<i>TABLE 106 GLOBAL MARKET FOR DNA MICROARRAYS BY SUBSTRATE MATERIAL, THROUGH 2020 (\$ MILLIONS)</i>	213
PROTEIN MICROARRAYS MARKETS	213
INTRODUCTION	213
<i>TABLE 107 COMPETITIVE PLATFORMS BY MULTIPLEXING DENSITY</i>	214
PROTEIN MICROARRAYS MARKET BY END-USE INDUSTRY	215
<i>TABLE 108 GLOBAL MARKET FOR PROTEIN MICROARRAYS BY END USE, THROUGH 2020 (\$ MILLIONS)</i>	215
PROTEIN MICROARRAYS MARKET BY SUBSTRATE MATERIAL	216
<i>TABLE 109 GLOBAL MARKET FOR PROTEOMIC MICROARRAYS BY SUBSTRATE MATERIAL, THROUGH 2020 (\$ MILLIONS)</i>	217
<i>TABLE 110 COMPETITORS OF COATED MICROARRAY SLIDE MARKET PRINCIPAL</i>	217
PROTEOMIC MICROARRAYS MARKET BY ARRAY TYPE	218
<i>TABLE 111 GLOBAL CONTRIBUTION OF PROTEOMIC ARRAYS BY ARRAY TYPE, 2015 (%)</i>	218
EMERGING MICROARRAYS MARKETS	219
EMERGING MICROARRAYS MARKET BY TECHNOLOGY	219
<i>TABLE 112 GLOBAL CONTRIBUTION OF EMERGING ARRAYS BY ARRAY TYPE, 2015 (%)</i>	219
EMERGING MICROARRAYS MARKETS BY END-USE INDUSTRY	220
<i>TABLE 113 GLOBAL MARKET FOR EMERGING ARRAYS BY END USE, THROUGH 2020 (\$ MILLIONS)</i>	220
EMERGING ARRAYS MARKET BY SUBSTRATE TYPE	220
<i>TABLE 114 GLOBAL MARKET FOR EMERGING ARRAYS BY SUBSTRATE MATERIAL, THROUGH 2020 (\$ MILLIONS)</i>	221
LOAC MARKETS	221
GENOMICS LOAC MARKET BY END-USE INDUSTRY	221
<i>TABLE 115 GLOBAL MARKET FOR GENOMICS LAB-ON-A-CHIP BY END-USER INDUSTRY, THROUGH 2020 (\$ MILLIONS)</i>	222
GENOMICS LOAC MARKET BY SUBSTRATE TYPE	223
<i>TABLE 116 GLOBAL MARKET FOR GENOMICS LOAC BY SUBSTRATE MATERIAL, THROUGH 2020 (\$ MILLIONS)</i>	223
PROTEOMICS LOAC MARKET BY END-USE INDUSTRY	224
<i>TABLE 117 GLOBAL MARKET FOR PROTEOMIC LOAC BY END-USER INDUSTRY, THROUGH 2020 (\$ MILLIONS)</i>	224
PROTEOMICS LOAC MARKET BY SUBSTRATE TYPE	225
<i>TABLE 118 GLOBAL MARKET FOR PROTEOMICS LOAC BY SUBSTRATE MATERIAL, THROUGH 2020 (\$ MILLIONS)</i>	225
NGS MARKETS	226

TOPIC	PAGE NO.
NGS MARKETS BY END-USER INDUSTRY	226
<i>TABLE 119 GLOBAL MARKET FOR THE NGS MARKET BY END-USER INDUSTRY, THROUGH 2020 (\$ MILLIONS)</i>	227
NGS MARKET BY SUBSTRATE TYPE	228
<i>TABLE 120 GLOBAL MARKET FOR NGS BY SUBSTRATE MATERIAL, THROUGH 2020 (\$ MILLIONS)</i>	228
NGS MARKETS BY TEST COMPLEXITY	229
<i>TABLE 121 GLOBAL CONTRIBUTION OF NGS BY TEST COMPLEXITY, 2015 (%)</i>	229
BIOCHIPS DIAGNOSTICS MARKETS	231
INTRODUCTION	231
DIAGNOSTICS MARKET BY BIOCHIP TYPE	231
<i>TABLE 122 GLOBAL MARKET FOR DIAGNOSTICS ASSAYS BY BIOCHIP TYPE, THROUGH 2020 (\$ MILLIONS)</i>	231
<i>TABLE 123 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS</i>	233
DIAGNOSTICS MARKET BY INDICATION	234
<i>TABLE 124 GLOBAL CONTRIBUTION OF DIAGNOSTICS MARKET BY INDICATION, 2015 (%)</i>	234
DIAGNOSTICS MARKET BY SUBSTRATE MATERIAL	239
<i>TABLE 125 GLOBAL CONTRIBUTION OF DIAGNOSTICS MARKET BY SUBSTRATE MATERIAL, 2015 (%)</i>	239
CANCER DIAGNOSTICS MARKET BY BIOCHIP TYPE	239
<i>TABLE 126 GLOBAL CONTRIBUTION OF CANCER DIAGNOSTICS MARKET BY BIOCHIP TYPE, 2015 (%)</i>	240
CANCER DIAGNOSTICS MARKET BY INDICATION	241
<i>TABLE 127 GLOBAL CONTRIBUTION OF CANCER DIAGNOSTICS MARKET BY INDICATION, 2015 (%)</i>	241
<i>TABLE 128 STATUS OF PROTEOMICS-BASED DIAGNOSTICS FOR CANCER APPLICATIONS, 2015</i>	242
BIOCHIPS MARKETS BY REGION	243
REGIONAL MARKET SUMMARY	243
<i>TABLE 129 GLOBAL MARKET FOR BIOCHIPS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	243
MICROARRAY MARKET BY REGION	245
<i>TABLE 130 GLOBAL MARKET FOR MICROARRAY MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	245
LOAC MARKET BY REGION	246
<i>TABLE 131 GLOBAL MARKET FOR LOAC BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	247
NGS MARKET BY REGION	248
<i>TABLE 132 GLOBAL MARKET FOR NGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	248
CHAPTER 10 BIOCHIPS PATENTS	251
MICROARRAY PATENTS	251
<i>TABLE 133 DNA MICROARRAY PATENTS BY REGION, 2002-2012 (NO.)</i>	251
<i>TABLE 134 MICROARRAY-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012 (NO.)</i>	252
<i>TABLE 135 MICROARRAY-RELATED PATENTS BY APPLICATION AND TITLE, 2013-2015</i>	252
LOAC PATENTS	255
<i>TABLE 136 LOAC-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012 (NO.)</i>	255
<i>TABLE 137 LOAC-RELATED PATENTS BY APPLICATION AND TITLE, 2013-2015</i>	255

TOPIC	PAGE NO.
CLINICAL NEXT-GENERATION SEQUENCING PATENTS	256
CLINICAL NGS PATENTS SUMMARY	257
<i>TABLE 138 CLINICAL NEXT-GENERATION SEQUENCING PATENTS, 2002-2012 (NO.)</i>	257
<i>TABLE 139 CLINICAL NGS-RELATED PATENTS BY APPLICATION AND TITLE, 2013-2015</i>	257
CLINICAL NGS PATENTS BY INDICATION	258
<i>TABLE 140 CLINICAL NEXT-GENERATION SEQUENCING PATENTS BY INDICATION, 2002-2012 (NO.)</i>	259
CHAPTER 11 COMPANY PROFILES	261
3QBD	261
20/20 GENE SYSTEMS INC.	261
ABAXIS INC.	262
ABBOTT LABORATORIES	263
ABIONIC SA	263
ABTECH SCIENTIFIC INC.	264
ABACUS DIAGNOSTICA LTD.	265
ACCELERATE DIAGNOSTICS INC.	265
ACEA BIOSCIENCES INC.	265
ACHIRA LABS PVT. LTD.	266
ADVANCED LIQUID LOGIC	266
AFFYMETRIX INC.	267
AGENDIA BV	268
<i>TABLE 141 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE</i>	269
AGENIX LTD.	270
AGILENT TECHNOLOGIES INC.	270
AKONNI BIOSYSTEMS	271
<i>TABLE 142 AKONNI BIOCHIP GRANTS</i>	272
ALERE TECHNOLOGIES GMBH	273
ALLEGRO DIAGNOSTICS CORP.	274
ALMAC GROUP, LTD.	275
ANALYTIK JENA AG	276
AQUAMARIJIN MICRO FILTRATION BV	276
AQUILA DIAGNOSTIC SYSTEMS INC.	277
ARRAYIT CORPORATION	277
ASSURERX HEALTH INC.	279
ATONOMICS A/S	279
AUSHON BIOSYSTEMS INC.	279
AUTOGENOMICS INC.	280
AVACTA GROUP PLC	281
AVIANA MOLECULAR TECHNOLOGIES	281
AXELA INC.	282
AYOXXA BIOSYSTEMS GMGH	283
BECKMAN COULTER INC.	283
BECTON, DICKINSON AND CO.	284
BIOCARTIS NV	285
BIOCEPT INC.	286
BIODOT INC.	287

TOPIC	PAGE NO.
BIOFIRE DIAGNOSTICS INC.	287
BIOFLUIDIX GMBH	288
BIOFORCE NANOSCIENCES INC.	288
BIOMERIEUX SA	288
BIONANOGENOMICS INC.	289
BIORAD LABORATORIES INC.	290
BIOSCALE INC.	291
BIOSURFIT SA	291
BIOSYSTEMS INTERNATIONAL	292
BIOTRAY	292
BLUE4GREEN	293
BODITECH MED INC.	293
BOEHRINGER INGELHEIM MICROPARTS GMBH	294
BOSTON MICROFLUIDICS	294
CAMBRIDGE BIOMAGNETICS LTD.	294
CANCER GENETICS INC.	295
CAPITALBIO CORPORATION	296
CARIS LIFE SCIENCES	297
CBC COMPREHENSIVE BIOMARKER CENTER GMBH	297
CELLANYX DIAGNOSTICS INC.	297
CELLASIC	298
CELLECTRICON AB	298
CELLIX, LTD.	299
CELLSCAPE CORPORATION	299
CELLULAR RESEARCH INC.	300
CELULA INC.	300
CEPHEID	301
CLEARBRIDGE BIOMEDICS	302
COMBIMATRIX MOLECULAR DIAGNOSTICS INC.	302
COURTAGEN LIFE SCIENCES INC.	303
CREATIVE MICROSYSTEMS CORPORATION	304
CUSTOMARRAY INC.	304
CYBRDI INC.	304
CYCLOFLUIDIC LTD.	305
CYNVENIO BIOSYSTEMS INC.	305
CYTOCENTRICS BIOSCIENCE	306
CYTOO SA	306
DEBIOTECH S.A.	307
DELTADOT LTD.	307
DEOS LABS	308
DIAGENIC ASA	308
DIAGNOSTICS FOR ALL	309
DIAGNOSWISS S.A.	309
DIAXONHIT	310
DNA ELECTRONICS LTD.	311
DNA LINK INC.	311
DNAMICROARRAY INC.	312

TOPIC	PAGE NO.
DOLOMITE MICROFLUIDICS LTD.	312
DR. CHIP BIOTECH INC.	313
DST DIAGNOSTISCHE SYSTEME & TECHNOLOGIEN GMBH	314
DYCONEX AG	314
EKSIGENT	315
ELVEFLOW	315
ELIM BIOPHARMACEUTICALS INC.	315
EMULATE INC.	316
EPIGEM LTD.	316
EPOCAL INC.	316
EUROIMMUN AG	317
FALCON GENOMICS INC.	317
FLUIDIGM CORPORATION	318
FLUIDWARE TECHNOLOGIES INC.	319
FLUIMEDIX APS	319
FLUXION BIOSCIENCES INC.	320
FULL MOON BIOSYSTEMS INC.	320
GEN9 INC.	321
GENALYTE	321
GENEFLUIDICS, INC.	322
GENENEWS	322
GENEPOC INC.	323
GENMARK DIAGNOSTICS, INC.	323
GENOMEDX BIOSCIENCES INC.	324
GENOMICA SAU	324
GIGAGEN INC.	325
GNUBIO INC.	326
GOOD START GENETICS INC.	326
GRACE BIO LABS	327
GRADIENSTECH AB	327
GWC TECHNOLOGIES INC.	327
GYROS AB	328
HNU-NANOPOINT	328
HOLOGIC INC.	329
ILLUMINA, INC.	329
IMMUNOVIA AB	331
INANOVATE INC.	332
INDX LIFECARE	332
INNOSIEVE DIAGNOSTICS BV	333
INSTITUTE OF MICROCHEMICAL TECHNOLOGY CO. LTD.	333
INTAVIS BIOANALYTICAL INSTRUMENTS AG	333
INTEL CORPORATION	334
IQUUM INC.	334
IRIS BIOTECHNOLOGIES INC.	335
ISU ABXIS CO. LTD.	336
JOHNSON & JOHNSON	336
JPT PEPTIDE TECHNOLOGIES GMBH	337

TOPIC	PAGE NO.
KINEXUS BIOINFORMATICS CORPORATION	338
LAB21 LTD.	339
LABORATORY CORPORATION OF AMERICA INC.	340
LC SCIENCES	341
LEUKODX LTD.	341
LIFE TECHNOLOGIES INC.	342
LINEAGEN INC.	344
LIONIX BV	345
LUMINEX	345
MAGARRAY, INC.	346
MAXWELL SENSORS INC.	347
MEDIMATE BV	347
MERCK KGAA	348
METAMARK GENETICS INC.	348
MICRO2GEN LTD.	349
MICROCHIPS INC.	349
MICRODISH BV	350
MICRODROP TECHNOLOGIES GMBH	350
MICROFAB TECHNOLOGIES INC.	350
MICROFLEXIS GMBH	351
MICROFLUIDIC CHIPSHOP GMBH	351
MICROFLUIDIC INNOVATIONS LLC	352
MICROFLUIDIX INC.	352
MICROLIQUID	353
MICROLYTIC	353
MICRONICS MICROFLUIDICS	353
MICRONIT MICROFLUIDICS BV	354
MICROPOINT BIOSCIENCES INC.	355
MICRUX TECHNOLOGIES SA	355
MINGYUAN MEDICARE DEVELOPMENT COMPANY LTD.	356
MOBIDIAG OY/LTD.	356
MODE DX LTD.	357
MOLECULAR CYTOMICS INC.	357
MYCROARRAY INC.	358
MYCROLAB DIAGNOSTICS PTY LTD.	358
NANION TECHNOLOGIES GMBH	359
NANO TERRA INC.	359
NANOBIOSYM	359
NANOBIOSYS	360
NANOCELLECT BIOMEDICAL INC.	360
NANOENTEK INC.	361
NANOIVD INC.	361
NANOMI BV	362
NANOMIX INC.	362
NANOSPEED DIAGNOSTICS INC.	363
NANOSPHERE INC.	363
NANOSTRING TECHNOLOGIES INC.	364

TOPIC	PAGE NO.
NEC CORPORATION	365
NEOGEN CORPORATION	365
NEOGENOMICS LABORATORIES	366
NETBIO INC.	366
NEXUS DX INC.	367
NOVARTIS	367
NUCLEA BIOTECHNOLOGIES INC.	367
OPKO HEALTH INC.	368
OPTOTRACK INC.	368
OSMOTEX AG	369
OSTENDUM R&D BV	369
OXFORD GENE TECHNOLOGY	370
PAMGENE INTERNATIONAL BV	371
PATHGEN DX PTE LTD.	371
PATHOGENETIX INC.	371
PATHOGENICA	372
PEPPERPRINT GMBH	373
PEPSCAN PRESTO BV	373
PERKINELMER	374
PHALANX BIOTECH GROUP	375
PHILIPS ELECTRONICS NV	376
PLEXERA LLC	376
POSITIVE ID CORPORATION	377
PROTAGEN AG	377
PROTEIN BIOTECHNOLOGIES INC.	378
PROTEUS DIGITAL HEALTH INC.	378
PROTNETEOMIX SAS	379
QIAGEN	379
Q-LINEA AB	380
QUANTERIX CORPORATION	380
QUANTISCIENTIFICS LLC	381
QUANTUM DX	381
QUEST DIAGNOSTICS	382
QWANE BIOSCIENCES S.A	383
RAINDANCE TECHNOLOGIES INC.	384
RANDOX LABORATORIES LTD.	385
RAYBIOTECH INC.	386
RETROGENIX LTD.	387
RHEONIX	387
RHEOSENSE INC.	387
RIDGE DIAGNOSTICS INC.	388
ROCHE HOLDING AG	388
ROSETTA GENOMICS INC.	389
<i>TABLE 143 ROSETTA'S DIAGNOSTICS TESTS</i>	389
SAMSUNG ELECTRONICS CO. LTD.	390
SANDSTONE DIAGNOSTICS INC.	390
SAVYON DIAGNOSTICS LTD.	391

TOPIC	PAGE NO.
SCIENION AG	391
SEEGENE INC.	392
<i>TABLE 144 SEEGENE BIOCHIPS COLLABORATIONS</i>	392
SENGENICS INTERNATIONAL PTE LTD	393
SENSIMED AG	394
SENSLAB GMBH	395
SENZAI B.V.	395
SFC FLUIDICS LLC	395
SHANGHAI BIOCHIP CO. LTD.	396
SHANGHAI HUAGUAN BIOCHIP CO. LTD.	396
SHARP CORPORATION	397
SIAMAB THERAPEUTICS INC.	397
SIGNAL GENETICS LLC	398
SIGNATURE DIAGNOSTICS AG	398
SILICON BIOSYSTEMS	399
SILOAM BIOSCIENCES INC.	399
SKYLINEDX	400
SLIPCHIP LLC	400
SOMALOGIC INC.	401
SOPHION BIOSCIENCE (BIOLIN SCIENTIFIC)	401
SPARTAN BIOSCIENCES INC.	402
SPHERE FLUIDICS LIMITED	403
SPHERE MEDICAL LTD.	403
SPINCHIP DIAGNOSTICS AS	403
SPINOMIX	404
SQI DIAGNOSTICS, INC.	404
SURMODICS INC.	405
SURNETICS	405
SYSMEX INOSTICS	405
T2 BIOSYSTEMS	406
TEARLAB CORPORATION	406
TECAN GROUP LTD.	407
THERMO FISHER SCIENTIFIC INC.	407
THINXXS MICROTECHNOLOGY AG	409
TIANJIN BIOCHIP CORPORATION	409
TIRF LABS INC.	409
TRANSGENOMIC INC.	410
TRANSLUME INC.	410
TRINEAN NV	411
TRINITY BIOTECH PLC	411
TROVAGENE INC.	412
US BIOMAX INC.	413
VERACYTE INC.	413
VEREDUS LABORATORIES PTE LTD.	413
WAFERGEN BIOSYSTEMS INC.	414
WASATCH MICROFLUIDICS	415
WAVE 80 BIOSCIENCES	416

TOPIC	PAGE NO.
WUXI BUOSHENG BIO-ENGINEERING CO. LTD.	416
XAGENIC INC.	416
XONA MICROFLUIDICS LLC	417
YMC CO. LTD.	417
ZELLKRAFTWERK GMBH	418
ZYOMYX, INC.	418
ZYOXEL LTD.	419

LIST OF TABLES

TABLE HEADING	PAGE NO.
TABLE A SCOPE OF REPORT	3
SUMMARY TABLE GLOBAL MARKET FOR BIOCHIP PRODUCTS BY END USE, THROUGH 2020 (\$ MILLIONS)	7
TABLE 1 BIOLOGY DOWNSIZING REVOLUTION	11
TABLE 2 COMPARISON OF TWO MAJOR BIOCHIP TYPES	12
TABLE 3 BIOCHIP NOMENCLATURE	13
TABLE 4 GLOBAL MARKET FOR BIOCHIP PRODUCTS BY BIOCHIP TYPE, THROUGH 2020 (\$ MILLIONS)	14
TABLE 5 DRIVING FORCES FOR BIOCHIPS KEY MARKET GROWTH	16
TABLE 6 COMPARISON OF BIOCHIPS INDUSTRIES	16
TABLE 7 THE NANOSCALE WORLD	19
TABLE 8 TYPES OF MICROARRAY	19
TABLE 9 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES	20
TABLE 10 MICROARRAY GENOME CONTENT	23
TABLE 11 DNA MICROARRAY PLATFORM FEATURES	23
TABLE 12 APPLICATIONS OF DNA MICROARRAY	25
TABLE 13 COMPARISON OF GENETIC ANALYSIS TECHNOLOGIES	26
TABLE 14 SNP MEASUREMENT PLATFORMS	28
TABLE 15 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES	32
TABLE 16 WORKFLOW FOR A MICRO-RNA EXPERIMENT	34
TABLE 17 COMPARISON OF BEAD-BASED ARRAYS AND PLANAR MICROARRAYS	34
TABLE 18 PROTEIN MICROARRAY PLATFORMS	37
TABLE 19 PROTEIN MICROARRAYS AS RESEARCH TOOLS	38
TABLE 20 PRODUCT TYPES OF PROTEIN MICROARRAY	40
TABLE 21 TECHNICAL CHALLENGES OF PROTEIN MICROARRAY	42
TABLE 22 EMERGING MICROARRAY TECHNOLOGIES	44
TABLE 23 LOAC PRODUCT LIFE CYCLE STAGE	48
TABLE 24 BIOCHIPS SUBSTRATE MATERIALS	49
TABLE 25 TYPES OF LOAC	50
TABLE 26 WORKFLOW COMPARISON OF SELECTED NEXT-GENERATION DNA SEQUENCING PLATFORMS	55
TABLE 27 BIOCHIP CONTENT IN NEXT-GENERATION SEQUENCING MACHINES	55
TABLE 28 SEGMENTS OF LOAC MARKET	57
TABLE 29 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS	58
TABLE 30 TECHNICAL CHALLENGES OF LOAC TECHNOLOGY	59
TABLE 31 BIOCHIP KEY LIFE SCIENCES MARKET SEGMENTS	62
TABLE 32 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT	65
TABLE 33 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT	71
TABLE 34 DIAGNOSTICS PARADIGM SHIFT	75
TABLE 35 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC ASSAY	76
TABLE 36 BIOMARKERS USED IN BIOCHIP-BASED DIAGNOSTICS	77
TABLE 37 RATE OF ADOPTION OF DNA MICROARRAY DIAGNOSTICS TESTS	79
TABLE 38 COMPARISON OF DNA-BASED MDX PLATFORMS	81
TABLE 39 FACTORS AFFECTING PENETRATION OF NEXT-GENERATION FORMATS INTO THE MDX MARKET	82
TABLE 40 U.S. INCIDENCE FOR SELECTED CANCERS, 2012	87
TABLE 41 STATUS OF ADVANCED BLADDER CANCER DIAGNOSTICS	89

TABLE HEADING	PAGE NO.
TABLE 42 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION	92
TABLE 43 BREAST CANCER MDX TECHNOLOGY PLATFORMS	92
TABLE 44 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS	94
TABLE 45 STATUS OF ADVANCED HPV DIAGNOSTICS	99
TABLE 46 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER	102
TABLE 47 STATUS OF ADVANCED COLORECTAL CANCER DIAGNOSTICS	104
TABLE 48 MDX TECHNOLOGY PLATFORMS FOR DETECTING CUP	107
TABLE 49 STATUS OF ADVANCED KIDNEY CANCER DIAGNOSTICS	108
TABLE 50 STATUS OF ADVANCED LEUKEMIA DIAGNOSTICS	110
TABLE 51 STATUS OF LIVER CANCER NEXT-GENERATION DX TESTS	112
TABLE 52 STATUS OF ADVANCED LYMPHOMA CANCER DIAGNOSTICS	114
TABLE 53 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER (%)	114
TABLE 54 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS	116
TABLE 55 STATUS OF ADVANCED MELANOMA DIAGNOSTICS	120
TABLE 56 EARLY SCREENING TESTS FOR OVARIAN CANCER	122
TABLE 57 STATUS OF OVARIAN CANCER NEXT-GENERATION DIAGNOSTICS TESTS	123
TABLE 58 STATUS OF ADVANCED PANCREATIC CANCER DIAGNOSTICS	125
TABLE 59 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS	127
TABLE 60 STATUS OF ADVANCED THYROID CANCER DIAGNOSTICS	131
TABLE 61 NEXT-GENERATION DX TEST SUMMARY BY INDICATION AND TECHNOLOGY	132
TABLE 62 IMPORTANCE OF CYP GENES IN DRUG METABOLISM (%)	134
TABLE 63 STATUS OF ADVANCED WARFARIN CYP PHARMACOGENETIC DIAGNOSTICS	135
TABLE 64 STATUS OF MRSA AND C. DIFFICILE ADVANCED DIAGNOSTICS	138
TABLE 65 STATUS OF INFLUENZA ADVANCED DIAGNOSTICS	139
TABLE 66 STATUS OF CT/NG ADVANCED DIAGNOSTICS	141
TABLE 67 DIAGNOSTICS APPROACHES FOR ALZHEIMER'S DISEASE	143
TABLE 68 STATUS OF ALZHEIMER'S DISEASE ADVANCED DIAGNOSTICS TESTS	144
TABLE 69 BNP MOLECULAR DIAGNOSTICS TESTS FOR CONGESTIVE HEART FAILURE	146
TABLE 70 ADVANCED DIAGNOSTICS TESTS FOR CYSTIC FIBROSIS	148
TABLE 71 NEXT-GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS INDUSTRY	150
TABLE 72 HLA TESTING MARKET	152
TABLE 73 ACQUISITIONS IN THE BIOCHIPS INDUSTRY, 2012-2015	156
TABLE 74 MICROARRAY INDUSTRY STRATEGIC ALLIANCES, 2012-2013	160
TABLE 75 LOAC/NGS INDUSTRY STRATEGIC ALLIANCES, 2012-2013	164
TABLE 76 LOAC COMPETITOR LANDSCAPE	173
TABLE 77 LEADING LOAC INSTRUMENT MANUFACTURERS	175
TABLE 78 FORENSIC APPLICATIONS FOR LOAC-BASED DNA ANALYZERS	176
TABLE 79 LOAC DIAGNOSTICS INDUSTRY	177
TABLE 80 ION CHANNEL SCREENING INDUSTRY	178
TABLE 81 DIGITAL PCR INDUSTRY	179
TABLE 82 LOAC UNIVERSITY SPIN-OFFS	180
TABLE 83 KEY LOAC ACQUISITIONS BY LEADING LIFE SCIENCE COMPANIES	181
TABLE 84 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL PHASE	182
TABLE 85 SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY	184

TABLE HEADING	PAGE NO.
TABLE 86 LABEL-FREE DETECTION INDUSTRY	184
TABLE 87 NANOARRAY INDUSTRY	186
TABLE 88 KEY PEPTIDE MICROARRAY COMPANIES	187
TABLE 89 KEY ANTIBODY MICROARRAY COMPANIES	188
TABLE 90 ESTIMATED MARKET SHARE FOR KEY ANTIBODY REAGENTS COMPANIES, 2012	189
TABLE 91 MULTIPLEX PROTEIN IN VITRO DIAGNOSTICS COMPANIES	190
TABLE 92 CTC BIOCHIPS INDUSTRY	192
TABLE 93 NORTH AMERICAN TEST COSTS AND PRICES, 2014 (\$)	194
TABLE 94 NEXT-GENERATION SEQUENCING-BASED, NONINVASIVE PRENATAL DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2014 (%)	195
TABLE 95 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS	196
TABLE 96 POC CD4 INDUSTRY	197
TABLE 97 BIOCHIPS-BASED COMPANIES IN AGRICULTURAL INDUSTRY	198
TABLE 98 CHINA BIOCHIP INDUSTRY	201
TABLE 99 KEY MARKET GROWTH DRIVING FORCES FOR BIOCHIPS	204
TABLE 100 GLOBAL MARKET FOR BIOCHIP PRODUCTS BY TYPE, THROUGH 2020 (\$ MILLIONS)	205
TABLE 101 GLOBAL MARKET FOR BIOCHIPS BY END-USE INDUSTRY, THROUGH 2020 (\$ MILLIONS)	206
TABLE 102 PROPERTIES OF BIOCHIPS SUBSTRATE MATERIALS	207
TABLE 103 GLOBAL MARKET FOR BIOCHIPS BY SUBSTRATE MATERIAL, THROUGH 2020 (\$ MILLIONS)	207
TABLE 104 GLOBAL MARKET FOR DNA MICROARRAYS BY END USE, THROUGH 2020 (\$ MILLIONS)	208
TABLE 105 GLOBAL CONTRIBUTION OF DNA MICROARRAYS BY ANALYSIS TYPE, 2015 (%)	210
TABLE 106 GLOBAL MARKET FOR DNA MICROARRAYS BY SUBSTRATE MATERIAL, THROUGH 2020 (\$ MILLIONS)	213
TABLE 107 COMPETITIVE PLATFORMS BY MULTIPLEXING DENSITY	214
TABLE 108 GLOBAL MARKET FOR PROTEIN MICROARRAYS BY END USE, THROUGH 2020 (\$ MILLIONS)	215
TABLE 109 GLOBAL MARKET FOR PROTEOMIC MICROARRAYS BY SUBSTRATE MATERIAL, THROUGH 2020 (\$ MILLIONS)	217
TABLE 110 COMPETITORS OF COATED MICROARRAY SLIDE MARKET PRINCIPAL	217
TABLE 111 GLOBAL CONTRIBUTION OF PROTEOMIC ARRAYS BY ARRAY TYPE, 2015 (%)	218
TABLE 112 GLOBAL CONTRIBUTION OF EMERGING ARRAYS BY ARRAY TYPE, 2015 (%)	219
TABLE 113 GLOBAL MARKET FOR EMERGING ARRAYS BY END USE, THROUGH 2020 (\$ MILLIONS)	220
TABLE 114 GLOBAL MARKET FOR EMERGING ARRAYS BY SUBSTRATE MATERIAL, THROUGH 2020 (\$ MILLIONS)	221
TABLE 115 GLOBAL MARKET FOR GENOMICS LAB-ON-A-CHIP BY END-USER INDUSTRY, THROUGH 2020 (\$ MILLIONS)	222
TABLE 116 GLOBAL MARKET FOR GENOMICS LOAC BY SUBSTRATE MATERIAL, THROUGH 2020 (\$ MILLIONS)	223
TABLE 117 GLOBAL MARKET FOR PROTEOMIC LOAC BY END-USER INDUSTRY, THROUGH 2020 (\$ MILLIONS)	224
TABLE 118 GLOBAL MARKET FOR PROTEOMICS LOAC BY SUBSTRATE MATERIAL, THROUGH 2020 (\$ MILLIONS)	225

TABLE HEADING	PAGE NO.
TABLE 119 GLOBAL MARKET FOR THE NGS MARKET BY END-USER INDUSTRY, THROUGH 2020 (\$ MILLIONS)	227
TABLE 120 GLOBAL MARKET FOR NGS BY SUBSTRATE MATERIAL, THROUGH 2020 (\$ MILLIONS)	228
TABLE 121 GLOBAL CONTRIBUTION OF NGS BY TEST COMPLEXITY, 2015 (%)	229
TABLE 122 GLOBAL MARKET FOR DIAGNOSTICS ASSAYS BY BIOCHIP TYPE, THROUGH 2020 (\$ MILLIONS)	231
TABLE 123 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS	233
TABLE 124 GLOBAL CONTRIBUTION OF DIAGNOSTICS MARKET BY INDICATION, 2015 (%)	234
TABLE 125 GLOBAL CONTRIBUTION OF DIAGNOSTICS MARKET BY SUBSTRATE MATERIAL, 2015 (%)	239
TABLE 126 GLOBAL CONTRIBUTION OF CANCER DIAGNOSTICS MARKET BY BIOCHIP TYPE, 2015 (%)	240
TABLE 127 GLOBAL CONTRIBUTION OF CANCER DIAGNOSTICS MARKET BY INDICATION, 2015 (%)	241
TABLE 128 STATUS OF PROTEOMICS-BASED DIAGNOSTICS FOR CANCER APPLICATIONS, 2015	242
TABLE 129 GLOBAL MARKET FOR BIOCHIPS BY REGION, THROUGH 2020 (\$ MILLIONS)	243
TABLE 130 GLOBAL MARKET FOR MICROARRAY MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)	245
TABLE 131 GLOBAL MARKET FOR LOAC BY REGION, THROUGH 2020 (\$ MILLIONS)	247
TABLE 132 GLOBAL MARKET FOR NGS BY REGION, THROUGH 2020 (\$ MILLIONS)	248
TABLE 133 DNA MICROARRAY PATENTS BY REGION, 2002-2012 (NO.)	251
TABLE 134 MICROARRAY-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012 (NO.)	252
TABLE 135 MICROARRAY-RELATED PATENTS BY APPLICATION AND TITLE, 2013-2015	252
TABLE 136 LOAC-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012 (NO.)	255
TABLE 137 LOAC-RELATED PATENTS BY APPLICATION AND TITLE, 2013-2015	255
TABLE 138 CLINICAL NEXT-GENERATION SEQUENCING PATENTS, 2002-2012 (NO.)	257
TABLE 139 CLINICAL NGS-RELATED PATENTS BY APPLICATION AND TITLE, 2013-2015	257
TABLE 140 CLINICAL NEXT-GENERATION SEQUENCING PATENTS BY INDICATION, 2002-2012 (NO.)	259
TABLE 141 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE	269
TABLE 142 AKONNI BIOCHIP GRANTS	272
TABLE 143 ROSETTA'S DIAGNOSTICS TESTS	389
TABLE 144 SEEGENE BIOCHIPS COLLABORATIONS	392

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET TRENDS FOR BIOCHIP PRODUCTS BY END USE, 2014-2020 (\$ MILLIONS)	8
FIGURE 1 MICROARRAY FEATURE DENSITY	22
FIGURE 2 MICROARRAY RESOLUTION	22
FIGURE 3 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES AT MAF5 AND MAF1	27
FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS`	30
FIGURE 5 IMPORTANCE OF PROTEINS	35
FIGURE 6 PROTEIN ANALYSIS APPROACHES CONTRASTED	36
FIGURE 7 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE	64
FIGURE 8 VALIDATION GAP FOR FUTURE DRUG TARGETS	73
FIGURE 9 SENSITIVITY AND SPECIFICITY	85
FIGURE 10 ENTRIES TO MIRNA DATABASE, 2002-2014 (NO.)	212